Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
Noteworthy the transient downregulation of the regulatory CK
2019-11-12

Noteworthy, the transient downregulation of the regulatory CK2β subunit reduces HSP27 expression in all the three different human cell lines (Fig. 2b). Similarly, the downregulation of one of the two catalytic subunits, CK2α or CK2α′, is sufficient to affect HSP27 expression without affecting other
-
Interestingly selective ETA blockade increased cutaneous
2019-11-12

Interestingly, selective ETA blockade increased cutaneous blood flow as measured by laser Doppler fluxmetry. This is a measure of total blood flow in the different vessels in the skin including venules, 5-Methoxy-CTP receptor as well as arterioles. This finding is in accordance with the previous dem
-
br Experimental Procedures br Author Contributions M M
2019-11-12

Experimental Procedures Author Contributions M.M. and M.T. designed and supervised the study. S.I. conducted the analysis on NOG-rd mice. H.-Y.T., M.F., and T.M. conducted and analyzed MEA. S.I., H.-Y.T., and M.M. performed 3D image analysis. N.K., T.K., M.G., and R.T. planned and established
-
br Author Contributions br Acknowledgments This work
2019-11-12

Author Contributions Acknowledgments This work was supported, in part, by a grant from the National Cancer Institute of the National Institutes of Health under Grant U01CA202241 and National Institutes of Health under Grant R01NS083856. Introduction The Eph (erythropoietin-producing human
-
Another notable finding in this study is that Cbl b
2019-11-12

Another notable finding in this study is that Cbl-b-mediated ubiquitination accelerates the degradation of phosphorylated DDR2. Cbl family has been documented to facilitate RTK degradation either in proteasome through K48-linked poly-ubiquitination or in lysosome through mono-, multiple mono- and K6
-
br The role of chemokine and AD Chemokines
2019-11-12

The role of chemokine and AD Chemokines are small cytokine proteins that are involved in various immunological and physiological functions. These proteins can be involved in cell migration and localization during homeostasis and inflammation, and as such, they were named chemokines [80]. Chemokin
-
br Materials and methods br Results br Discussion Our
2019-11-12

Materials and methods Results Discussion Our study assessed the cytokine and chemokine changes associated with first onset PP as compared to HP and HNP groups. In the monocytes/ macrophages/ dendritic Wiskostatin panel, IL-6 levels were found to be significantly elevated in both HP and PP
-
A number of immune relevant
2019-11-12

A number of immune-relevant genes have been studied to explore the immunologic mechanisms in large yellow croakers; however, the chemokine receptor CXCR family has never been studied in this organism. Chemokines are a large superfamily of chemotactic cytokines that are utilized to direct the traffic
-
Prostaglandins PGs are lipid mediators
2019-11-12

Prostaglandins (PGs) are lipid mediators that exhibit a variety of physiological properties by interacting specific G protein-coupled receptors (GPCRs) [10]. PGD2 is synthesized from PGH2 through two distinct PGD synthases; lipocalin-type PGD synthase (L-PGDS) and hematopoietic PGD synthase (H-PGDS)
-
br Clinical trials of CRM inhibitors KPT clinical
2019-11-12

Clinical trials of CRM1 inhibitors KPT-330 clinical trials have been initiated with promising very early results. One trial includes patients with advanced solid tumors whose disease has progressed after at least one prior therapy for metastatic disease (NCT01607905). Another trial includes patie
-
The third challenge is to understand
2019-11-12

The third challenge is to understand the mechanisms of drug resistance. There are several different mechanisms of ES tumor to develop drug resistance. First, cancer stem cells are capable of proliferate and generate tumor cells with new sets of mutations which may harbor different protein targets [1
-
In the context of our ongoing studies to define the
2019-11-11

In the context of our ongoing studies to define the phytochemical and biological properties of oxyprenylated secondary metabolites of plant and fungal origin, we wish to report herein the investigation on the interaction of some natural and semisynthetic O-alkylcoumarins with promising ChE inhibitor
-
Ten non FH ADH probands fulfilled
2019-11-11

Ten non-FH ADH probands fulfilled the diagnostic criteria of hyperabsorbers. Table 2 shows the main lipid characteristics of these subjects and of 10 non-hyperabsorber probands used for comparison. There were differences between groups in body mass index, waist circumference and triglycerides. Other
-
br The estrogen receptors History and discovery
2019-11-11

The estrogen receptors: History and discovery In 1958, Elwood Jensen discovered the estrogen receptor, the first receptor ever encountered for any hormone, by showing that reproductive female tissues were able to uptake estrogen from the circulation by binding to proteins. He later demonstrated t
-
GSK1210151A MAPKs are a family of phosphorylating enzymes th
2019-11-11

MAPKs are a family of phosphorylating enzymes that orchestrate various cellular response in proliferation, apoptosis, inflammation, stress response, and energy metabolism [11]. There are at least four major members including extracellular signal-regulated kinase 1 and 2 (ERK1/2), p38 mitogen-activat
15185 records 945/1013 page Previous Next First page 上5页 941942943944945 下5页 Last page